Edema

Edema is a clinically visible increase in interstitial fluid volume, produced by expansion of total-body sodium — and the water that follows it — beyond what the interstitium can accommodate without becoming apparent on exam. Firm fingertip pressure that leaves a visible indentation defines pitting edema; when no indentation forms, it is nonpitting, a clue that points away from simple volume overload toward lymphatic obstruction or myxedema instead. Severe, generalized edema is called anasarca. The single most important branch point in evaluating any patient with edema is whether it is unilateral or bilateral: unilateral edema points toward a local structural problem — deep vein thrombosis, chronic venous insufficiency, lymphedema, or local infection/inflammation — while bilateral edema points toward a systemic cause such as heart failure, cirrhosis, nephrotic syndrome or another significant kidney disease, hypoalbuminemia, hypothyroidism, or a causative medication. Edema is a sign, not a diagnosis in itself — the underlying disorder must be identified and treated concurrently with any therapy directed at the fluid.^[1]

Examination technique

Apply firm fingertip pressure over a bony surface — classically the anterior tibia — for several seconds. Pitting edema leaves a visible, palpable indentation that resolves over seconds; nonpitting edema does not indent, and should prompt consideration of lymphedema or hypothyroidism (myxedema) rather than simple volume overload.

Distribution

Edema follows gravity and body position: it appears first in the feet and ankles in an ambulatory patient, over the sacrum in a patient who is recumbent, and in the scrotum in a supine man with significant fluid overload. Periorbital edema, especially noticed on waking, is a classic early sign of nephrotic-range proteinuria. Fluid can also compartmentalize into a body cavity instead of (or in addition to) subcutaneous tissue — ascites (peritoneal), pleural effusion, or pericardial effusion.

• Systemic conditions: heart failure, cirrhosis or other hepatic dysfunction, nephrotic syndrome or other significant kidney disease, hypothyroidism, pregnancy, hypoalbuminemia (malnutrition, protein-losing states), and capillary-leak states.
• Localized conditions: venous or lymphatic obstruction (including malignancy compressing venous/lymphatic drainage), deep vein thrombosis, chronic venous insufficiency, infection or inflammation, and sequelae of prior limb surgery or vascular-access procedures.
• Medications — a large, genuinely pharmacist-relevant list; see Assessment & Diagnosis and Drug Tables for the full medication-class breakdown.
• High dietary sodium intake relative to the ability to excrete it.
• Prolonged standing or sitting, immobility, and obesity — particularly relevant to idiopathic edema, which occurs almost exclusively in this group.
• Advanced age and polypharmacy, which increase both the prevalence of edema-associated comorbidities and cumulative exposure to edema-causing medications.

History

• Onset, duration, and whether the edema is unilateral or bilateral (see Recognize the Condition) — this single question narrows the differential more than any other.
• Ask specifically about conditions associated with edema: known kidney, heart, or liver disease; pregnancy; low serum albumin or a protein-losing condition; a capillary-leak state; and hypothyroidism.
• For unilateral edema, ask about recent immobility or travel, active malignancy, prior lymph node dissection or radiation, prior limb surgery or vascular-access procedures, and any signs of infection or inflammation.
• Take a careful dietary sodium history.
• Take a complete medication history, including nonprescription products and natural health products — medication-induced edema is common, frequently missed, and often reversible simply by identifying and addressing the causative drug (see the medication table below).

Physical examination

• Weight — the single most sensitive measure of change in total-body fluid, and the basis for tracking response to therapy.
• Blood pressure and heart rate — hypertension is a feature of expanded extracellular fluid volume (ECFV); hypotension, especially a postural drop, suggests contracted ECFV instead.
• Respiratory rate and oxygen saturation.
• Skin turgor and skin appearance (shine or taut skin over expanded tissue).
• Jugular venous pressure — elevated JVP, along with ascites and pleural effusion, are features of ECFV expansion; loss of skin turgor with a low JVP instead suggests ECFV contraction.
• Abdominal exam and percussion for ascites; chest percussion/auscultation for a pleural effusion.
• Characterize the edema itself: pitting vs nonpitting, symmetric vs asymmetric, and its distribution.

Laboratory investigations

• Electrolytes — sodium, potassium, chloride, bicarbonate, calcium, and magnesium.
• Urea and creatinine (kidney function), and uric acid.
• Urinalysis, specifically looking for significant albuminuria (nephrotic syndrome).
• Liver function tests, with particular attention to markers of synthetic hepatic function — INR, albumin, and ammonia.
• TSH, fasting blood glucose, and a lipid profile.
• A natriuretic peptide (BNP or NT-proBNP) to screen for a cardiac cause.
• Serum albumin — low in liver disease or a proteinuric kidney disease.
• A 24-hour urine collection to quantify proteinuria and sodium excretion when signs/symptoms suggest a primary or secondary kidney disorder, or to confirm dietary sodium adherence during a resistant-edema workup.

Imaging

• Chest x-ray — assesses cardiac size and pulmonary status.
• Point-of-care ultrasound (POCUS) — lung POCUS can identify interstitial edema and pleural effusion; cardiac POCUS can identify pericardial effusion; inferior vena cava imaging gives a rapid estimate of central venous pressure/volume status.
• Compression ultrasonography of the affected limb whenever unilateral edema raises concern for deep vein thrombosis.

When testing is not needed

A patient with mild, bilateral, pitting edema, a clearly identified recently-started causative medication, an otherwise normal history and exam, and no red flags does not need the full systemic laboratory/imaging workup above before a trial of discontinuing or switching the offending drug. Reserve the complete workup for edema without an obvious explanation, edema that persists despite an appropriate medication change, or edema with any red-flag feature.^[1]

Medications that can cause or worsen edema

Drug-induced peripheral edema is common and frequently under-recognized — always review the medication list before assuming new or worsening edema reflects a new or worsening systemic disease.^[2]

Full medication-class reference

• Decrease excess extracellular fluid volume and reduce or eliminate visible edema, at a controlled and physiologically safe rate.
• Identify and directly treat the underlying cause of the edema in parallel with any symptomatic fluid-directed therapy.
• Improve patient comfort and mobility, and prevent edema-related skin breakdown or infection.
• Avoid iatrogenic harm from diuretic therapy — intravascular volume depletion, electrolyte disturbance, and prerenal azotemia.
• Recognize and manage diuretic resistance early rather than continuing an ineffective regimen.

• Sodium restriction to under 88 mmol/day (2 g sodium, or 5 g sodium chloride) is the foundation of therapy for any volume-overload-related edema — a diuretic will not work if sodium intake continues to exceed what is being excreted.
• Fluid restriction, individualized to the patient's volume status and disease state — particularly important, and generally under 1 L/day, when significant hyponatremia (sodium under 130 mmol/L) is also present.
• Avoid the supine position in decompensated heart failure, especially at night, since it augments venous return and can worsen orthopnea/paroxysmal nocturnal dyspnea — advise a more upright sleeping position instead.
• Leg elevation above the level of the heart when resting, to promote venous and lymphatic return.
• 1st line for venous insufficiency and lymphedema compression therapy: a medium-pressure compression stocking (20-30 mmHg) for most patients with venous insufficiency; complete decongestive therapy (manual lymphatic drainage, multilayer compression bandaging, exercise, and skin care) for confirmed lymphedema. Avoid high-pressure compression in significant peripheral arterial disease, where it can worsen limb ischemia — confirm adequate arterial perfusion before fitting a higher-pressure garment.^[3]
• Paracentesis for tense or refractory ascites, performed under specialist direction.
• Ultrafiltration therapy for significant, diuretic-refractory volume overload in the setting of kidney insufficiency — refer to a specialist.
• Meticulous skin care and prompt treatment of any skin breakdown in lymphedema, to reduce the risk of cellulitis and further lymphatic damage.

Pregnancy

Breastfeeding

Postpartum edema is usually self-limiting. When a diuretic is genuinely needed in a breastfeeding patient, hydrochlorothiazide and spironolactone both transfer into breast milk only in very low amounts, with no adverse infant effects reported, so either can be used; avoid intense diuresis, since in theory it can reduce milk supply through intravascular volume depletion.

Pediatrics

This chapter addresses adult edema evaluation and management. New pediatric edema needs pediatric-specific evaluation — nephrotic syndrome and congenital heart disease are more prominent considerations in this age group — refer to pediatrics or pediatric nephrology/cardiology rather than extrapolating adult dosing directly.

Renal impairment

Thiazide diuretics are ineffective as monotherapy once ClCr falls to 50 mL/min or under — a loop diuretic is required, often at a higher dose than in a patient with normal kidney function, since higher plasma concentrations are needed to deliver adequate drug into the tubular lumen. Avoid potassium-sparing diuretics (amiloride, spironolactone, eplerenone, finerenone) in significant kidney impairment given a substantially increased hyperkalemia risk; when they are used despite this, monitor potassium closely.

Hepatic impairment

Spironolactone combined with furosemide is the preferred regimen for cirrhotic ascites/edema (see Drug Tables). Avoid NSAIDs entirely in decompensated cirrhosis — they blunt diuretic response and increase acute kidney injury risk. Correct electrolyte disturbances promptly, since both hypokalemia and metabolic alkalosis can precipitate hepatic encephalopathy.

Older adults

Older patients are more susceptible to diuretic-induced dehydration, hypotension, falls, and thiazide-associated hyponatremia — start at the lower end of the dosing range and titrate more gradually, with closer monitoring.

Weigh the patient at baseline and regularly through treatment — daily during active diuresis, since weight is the most sensitive marker of fluid-status change. The maximum recommended rate of weight loss is 1 kg/day when significant peripheral edema is present, to avoid depleting intravascular volume faster than interstitial fluid can be mobilized into it.^[5]

Check electrolytes (sodium, potassium, chloride, bicarbonate, calcium, magnesium) and kidney function (urea, creatinine) before starting diuretic therapy, again within the first 1-2 weeks of starting or increasing the dose, and periodically thereafter — more frequently when initiating therapy, increasing the dose, adding a second diuretic, or when the patient is clinically unwell (vomiting, diarrhea, reduced oral intake).

Watch specifically for hypokalemia and hyponatremia with loop and thiazide diuretics — both are more common in the first 1-2 weeks of therapy and are usually asymptomatic, so they must be actively checked for rather than waited on — for hyperkalemia with potassium-sparing agents (especially in kidney impairment, diabetes, or with a concurrent ACE inhibitor/ARB), and for prerenal azotemia and metabolic alkalosis with any combination diuretic regimen.

Watch for signs of overdiuresis at every visit — confusion, dizziness, fatigue, hypotension, or weakness clinically, or laboratory evidence of prerenal azotemia, hypokalemia, or metabolic alkalosis — and hold the diuretic (and consider holding other antihypertensives), provide gentle hydration, and consider specialist referral if these develop.

Confirm the underlying cause of the edema is being actively addressed, not just the fluid itself, at every follow-up.

1. Confirm adherence to sodium restriction; a 24-hour urine sodium collection can objectively assess dietary adherence if genuinely uncertain.
2. Confirm adherence to fluid restriction if hyponatremia is present.
3. Confirm the prescribed diuretic regimen (drug, dose, and frequency) is actually being taken as directed.
4. Increase the loop diuretic dose incrementally — doubling the dose approximately every 3-5 days — until diuresis is achieved, recognizing that severe hypoalbuminemia (albumin under 20 g/L) or reduced kidney perfusion (kidney failure, heart failure) can impair delivery of the drug into the tubular lumen and blunt the response to an initial dose.
5. Increase dosing frequency to 2-3 times daily if diuresis is not sustained across the day, and double the dose when switching from IV to oral administration.
6. Consider IV dosing if the gut is edematous (impairing oral absorption) or in a low-cardiac-output state, and consider a continuous IV infusion in a critical-care setting.
7. Recognize that a maximum effective dose exists for every loop diuretic — beyond it, further dose increases add toxicity risk without meaningfully more diuresis. At that point, add a second diuretic rather than continuing to escalate the same agent.
8. Add a distally-acting diuretic (e.g., metolazone or another thiazide) to a loop diuretic for additive blockade at a second nephron site — give the oral thiazide 30-60 minutes before an IV loop diuretic dose, or at the same time if both are given orally.
9. Add a potassium-sparing diuretic if hypokalemia complicates therapy, with caution and frequent electrolyte monitoring in kidney failure, diabetes, or with concurrent ACE inhibitors, ARBs, beta-blockers, cyclosporine, NSAIDs, pentamidine, tacrolimus, or trimethoprim, given real hyperkalemia risk in combination.
10. Consider a carbonic anhydrase inhibitor (acetazolamide) as a specialist-directed addition when diuresis remains inadequate despite combination therapy, or when metabolic alkalosis is itself limiting further loop/thiazide titration — monitor bicarbonate and potassium closely given the risk of significant metabolic acidosis or hypokalemia.
11. If all of the above fail, refer for a specialist-directed procedural option: ultrafiltration for kidney failure, or paracentesis for cirrhotic ascites.

• Starting a diuretic for edema due to chronic venous insufficiency or lymphedema instead of compression therapy — diuretics do not correct the underlying mechanical problem.
• Missing a causative medication (a dihydropyridine calcium channel blocker, an NSAID, a thiazolidinedione, a gabapentinoid, or a corticosteroid are the highest-yield culprits) and adding a diuretic on top of an ongoing offending drug instead of addressing it directly.
• Using a fixed-dose combination diuretic product as first-line therapy — it is harder to titrate the individual components up or down as the patient's volume status changes.
• Diuresing faster than roughly 1 kg/day of weight loss, risking intravascular volume depletion out of proportion to interstitial fluid mobilization.
• Using a potassium-sparing diuretic in significant kidney impairment without close, frequent potassium monitoring.
• Missing early signs of overdiuresis (confusion, dizziness, hypotension, prerenal azotemia) and continuing to escalate the diuretic dose instead of reassessing.
• Treating unilateral edema as if it were bilateral/systemic — this misses deep vein thrombosis and lymphedema, which need their own specific workup and treatment.
• Assuming a thiazide diuretic will be effective as monotherapy once kidney function has fallen to a creatinine clearance of about 50 mL/min or under.
• Continuing, or repeatedly restarting, a diuretic in idiopathic edema despite evidence that stopping and starting is itself driving cyclical fluid shifts.
• Missing spontaneous bacterial peritonitis or another acute decompensation in a cirrhotic patient with rapidly worsening ascites, instead of simply increasing the diuretic dose.
• Using an NSAID in a patient on diuretic therapy for edema — it blunts the diuretic response and increases kidney injury risk.

How to use this table: Doses are adult doses and require patient-specific confirmation, including renal/hepatic adjustment. Select any drug name to open its complete Pharmasist Drug Database page.

Loop diuretics

Most potent diuretic class; first-choice for edema of cardiac, renal, or hepatic origin, and for any edema needing prompt volume reduction.

Thiazide and thiazide-like diuretics

First-line if ClCr is over 50 mL/min; ineffective as monotherapy once ClCr falls to 50 mL/min or under. Useful antihypertensive effect and useful add-on to a loop diuretic for resistant edema.

Potassium-sparing diuretics

Useful combined with a loop or thiazide diuretic for resistant edema, or to offset loop/thiazide-induced hypokalemia. Avoid in significant kidney impairment given hyperkalemia risk.

Carbonic anhydrase inhibitor

Specialist-directed only; reserved for diuresis that remains inadequate on combination loop/thiazide/potassium-sparing therapy, or when that combination has produced a metabolic alkalosis that is itself limiting further titration.

Vasopressin V2-receptor antagonist

The only selective vasopressin V2-receptor antagonist (vaptan) available in Canada. Reserve for volume overload with significant hyponatremia refractory to other measures, under specialist direction with close inpatient sodium monitoring — not first-line diuretic therapy.

Evidence note: Diuretic dosing, adverse effects, and comments reflect standard Canadian practice, cross-checked against current diuretic pharmacology literature.^[5]